We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+12.54%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$227M
AUM Growth
+$19.5M
Cap. Flow
+$4.57M
Cap. Flow %
2.01%
Top 10 Hldgs %
68.95%
Holding
44
New
16
Increased
2
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$15.7M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$7.53M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$7.5M
4
STML
Stemline Therapeutics, Inc.
STML
+$7.27M
5
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$6.98M

Top Sells

Rank Stock Value
1
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$14.9M
2
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$10.6M
3
ELGX
Endologix Inc
ELGX
+$9.94M
4
ARWR icon
Arrowhead Research
ARWR
+$8.32M
5
TOVX icon
Theriva Biologics
TOVX
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 48.68%
2 Technology 25.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNXR
1
DELISTED
Connecture, Inc.
CNXR
$57M 25.07%
5,502,965
– –
HPTX
2
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$22.9M 10.1%
500,000
-498,066
-50% -$14.9M
VNDA icon
3
Vanda Pharmaceuticals
VNDA
$307M
$12.9M 5.68%
+1,388,599
New +$15.7M
OFIX icon
4
Orthofix Medical
OFIX
$477M
$10.8M 4.74%
300,000
+190,000
+173% +$5.97M
ADMS
5
DELISTED
Adamas Pharmaceuticals
ADMS
$10.6M 4.68%
608,650
+437,834
+256% +$7.5M
OCRX
6
DELISTED
Ocera Therapeutics, Inc.
OCRX
$9.25M 4.07%
1,963,777
-1
-0% -$6
ALIM
7
DELISTED
Alimera Sciences
ALIM
$8.68M 3.82%
115,437
-59,220
-34% -$4.66M
AUPH icon
8
Aurinia Pharmaceuticals
AUPH
$1.91B
$8.51M 3.75%
1,941,144
-544,432
-22% -$2.16M
DSCI
9
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$8.28M 3.65%
977,923
-207,709
-18% -$1.77M
VCEL icon
10
Vericel Corp
VCEL
$2.35B
$7.72M 3.4%
2,086,028
-83,972
-4% -$286K
ARAV
11
DELISTED
Aravive, Inc. Common Stock
ARAV
$7.07M 3.11%
+64,167
New +$7.53M
SCMP
12
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$7M 3.08%
+450,000
New +$6.98M
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$6.88M 3.03%
+475,200
New +$7.27M
ARDM
14
DELISTED
Aradigm Corp Common Stock
ARDM
$6.34M 2.79%
1,002,962
– –
ASND icon
15
Ascendis Pharma A/S
ASND
$16B
$5.9M 2.59%
+339,863
New +$6.18M
ARCT icon
16
Arcturus Therapeutics
ARCT
$164M
$5.54M 2.44%
+140,541
New +$6.18M
DYAX
17
DELISTED
DYAX CORPORATION
DYAX
$3.95M 1.74%
+235,950
New +$3.67M
HRTX icon
18
Heron Therapeutics
HRTX
$93.9M
$3.93M 1.73%
+270,000
New +$3.04M
TENX icon
19
Tenax Therapeutics
TENX
$363M
$3.61M 1.59%
35
– –
AMPE
20
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$3.17M 1.4%
+1,405
New +$2.4M
ENTA icon
21
Enanta Pharmaceuticals
ENTA
$366M
$3.06M 1.35%
+100,000
New +$3.89M
EBS icon
22
Emergent Biosolutions
EBS
$373M
$2.96M 1.3%
102,791
-147,209
-59% -$4.22M
VIRX
23
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.54M 1.12%
+4,946
New +$2.5M
ATHX
24
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$2.39M 1.05%
+33,208
New +$2.01M
SSKN
25
DELISTED
Strata Skin Sciences
SSKN
$1.46M 0.64%
+11,392
New +$1.13M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2015 Portfolio in Review

As of Q1 2015, Great Point Partners held 44 positions worth $227M, up 9.4% from $208M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Great Point Partners's Q1 2015 filing shows 16 new, 2 increased, 10 reduced and 11 closed positions. Its largest new stake was Vanda Pharmaceuticals: 1,388,599 shares worth $12.9M. The largest sale was HYPERION THERAPEUTICS INC COM STK (DE), an estimated $14.9M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Technology.

  • Great Point Partners's largest Q1 2015 buy was Vanda Pharmaceuticals: 1,388,599 shares worth $12.9M.
  • Great Point Partners added most to Adamas Pharmaceuticals in Q1 2015, an estimated $7.5M increase.
  • Great Point Partners's biggest Q1 2015 reduction was HYPERION THERAPEUTICS INC COM STK (DE), cutting an estimated $14.9M.
  • Great Point Partners fully exited Infinity Pharmaceuticals, Inc. in Q1 2015, selling an estimated $10.6M.
  • Great Point Partners's ten largest holdings make up 69% of its $227M portfolio in Q1 2015.
  • Great Point Partners opened 16 new positions and closed 11 in Q1 2015.
  • Great Point Partners's portfolio value rose 9.4% quarter-over-quarter to $227M.

Based on Great Point Partners's 13F filing for Q1 2015, filed 15 May 2015.